预测腋窝对新辅助化疗的反应:淋巴结阳性乳腺癌患者的乳腺MRI与US
本研究为回顾性研究,纳入2015年1月至2017年9月间接受新辅助化疗后手术的临床淋巴结阳性乳腺癌女性408例,随机按7:3分为测试集与验证集,用多因素logistic回归建立预测残留腋窝淋巴结转移的临床模型。独立预测因素包括临床N2或N3期、新辅助化疗后US示腋窝淋巴结肿大、MRI示肿瘤缩小不足50%、Ki-67阴性、激素受体阳性及人表皮生长因子受体2阴性,模型在测试集与验证集的AUC分别为0.84(95%CI:0.79,0.88)与0.78(95%CI:0.70,0.87),简化风险评分为1分时假阴性率为5%-10%。
要点
- 临床N2或N3期、新辅助化疗后US示腋窝淋巴结肿大提示残留腋窝淋巴结转移风险较高。
- MRI示肿瘤缩小不足50%、Ki-67阴性、激素受体阳性及HER2阴性亦为独立预测因素。
- 模型在测试集AUC为0.84、验证集为0.78,简化风险评分1分时假阴性率为5%-10%。
核心结论
- 整合淋巴结分期、US表现、MRI反应及分子受体状态的预测模型对临床淋巴结阳性乳腺癌患者新辅助化疗后残留腋窝淋巴结转移显示出良好的诊断性能。
研究设计与样本
- 回顾性研究,纳入2015年1月至2017年9月接受新辅助化疗后手术的临床淋巴结阳性乳腺癌女性408例,随机按7:3分为测试集与验证集,采用单因素及多因素logistic回归分析独立预测因素并建立风险评分。
关键影像表现/征象
- 新辅助化疗后US示腋窝淋巴结肿大是残留腋窝淋巴结转移的独立预测因素(P < .05)。
- MRI示肿瘤缩小不足50%是残留腋窝淋巴结转移的独立预测因素(P < .05)。
诊断标准与关键数值
- 模型在测试集的AUC为0.84(95%CI:0.79,0.88),在验证集的AUC为0.78(95%CI:0.70,0.87)。
- 简化风险评分为1分时,假阴性率范围为5%-10%。
- 腋窝病理完全缓解率为56.6%(231/408)。
临床应用与阅片要点
- 阅片时需关注新辅助化疗后US腋窝淋巴结是否肿大及MRI肿瘤缩小程度,并结合临床N分期与分子受体状态综合评估残留腋窝淋巴结转移风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background In patients who are expected to achieve axillary pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC), omission of axillary lymph node (LN) dissection could prevent morbidity and complications. Purpose To develop a clinical model to predict residual axillary LN metastasis in patients with clinically node-positive breast cancer after NAC by using MRI and US. Materials and Methods In this retrospective study, women with clinically node-positive breast cancer who were treated with NAC following surgery between January 2015 and September 2017 were included. The patients were randomly assigned to a test and validation set (7:3 ratio). Univariable and multivariable logistic regression analyses were performed to evaluate the independent predictors of residual axillary LN metastasis in the test set. A prediction risk score was developed based on the odds ratios from the multivariable analysis and validated in both sets. Results A total of 408 women were included (mean age ± standard deviation, 47.9 years ± 9.6). The axillary pCR rate was 56.6% (231 of 408). Independent predictors of residual axillary LN metastasis were clinical stage N2 or N3, presence of axillary lymphadenopathy at US after NAC, tumor size reduction less than 50% at MRI, Ki-67 negativity, hormone receptor positivity, and human epidermal growth factor receptor 2 negativity (all, P < .05). In a model using these predictors, the area under the receiver operating characteristic curve in the test and validation sets was 0.84 (95% confidence interval: 0.79, 0.88) and 0.78 (95% confidence interval: 0.70, 0.87), respectively. When the patients had a simplified risk score of 1, the false-negative rates ranged between 5%-10%. Conclusion A prediction model incorporating nodal status stage, US finding, MRI response, and molecular receptor status shows good diagnostic performance for residual axillary lymph node metastasis after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Whitman in this issue.
引用
- Kim R, Chang JM, Lee HB, et al. Predicting Axillary Response to Neoadjuvant Chemotherapy: Breast MRI and US in Patients with Node-Positive Breast Cancer. Radiology. 2019. PMID: 31407967. doi:10.1148/radiol.2019190014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。